vs
Side-by-side financial comparison of SOLENO THERAPEUTICS INC (SLNO) and Youlife Group Inc. (YOUL). Click either name above to swap in a different company.
Youlife Group Inc. is the larger business by last-quarter revenue ($127.5M vs $66.0M, roughly 1.9× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 4.1%, a 35.3% gap on every dollar of revenue.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
SLNO vs YOUL — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.0M | $127.5M |
| Net Profit | $26.0M | $5.2M |
| Gross Margin | 98.3% | 14.1% |
| Operating Margin | 33.5% | 5.0% |
| Net Margin | 39.4% | 4.1% |
| Revenue YoY | — | — |
| Net Profit YoY | 134.0% | — |
| EPS (diluted) | $0.47 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $66.0M | — | ||
| Q2 25 | $32.7M | $127.5M |
| Q3 25 | $26.0M | — | ||
| Q2 25 | $-4.7M | $5.2M |
| Q3 25 | 98.3% | — | ||
| Q2 25 | 97.9% | 14.1% |
| Q3 25 | 33.5% | — | ||
| Q2 25 | -20.0% | 5.0% |
| Q3 25 | 39.4% | — | ||
| Q2 25 | -14.4% | 4.1% |
| Q3 25 | $0.47 | — | ||
| Q2 25 | $-0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.9M | $22.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $494.8M | $-55.7M |
| Total Assets | $599.9M | $148.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $498.9M | — | ||
| Q2 25 | $286.8M | $22.2M |
| Q3 25 | $494.8M | — | ||
| Q2 25 | $240.1M | $-55.7M |
| Q3 25 | $599.9M | — | ||
| Q2 25 | $332.3M | $148.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.5M | — |
| Free Cash FlowOCF − Capex | $43.5M | — |
| FCF MarginFCF / Revenue | 65.8% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $43.5M | — | ||
| Q2 25 | $-12.6M | — |
| Q3 25 | $43.5M | — | ||
| Q2 25 | $-12.6M | — |
| Q3 25 | 65.8% | — | ||
| Q2 25 | -38.6% | — |
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — |
| Q3 25 | 1.67× | — | ||
| Q2 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
